Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Binge Eating, Depression and Anxiety Outcomes After Sleeve Gastrectomy Versus Gastric Bypass: A Cohort Study

15 mei 2026 bijgewerkt door: Ahmed Eid Ali Ahmed Aziz, Cairo University

Binge Eating, Depression and Anxiety Outcomes Following Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y or One-Anastomosis Gastric Bypass: A Prospective Cohort Study

The goal of this clinical trial is to learn if the type of weight-loss surgery (sleeve gastrectomy or gastric bypass) affects binge eating, depression, and anxiety in adults with severe obesity. The main questions it aims to answer are:

Does sleeve gastrectomy lead to different changes in binge eating compared with gastric bypass?

Does the type of surgery lead to different changes in depression and anxiety symptoms?

Researchers will compare people who have sleeve gastrectomy with those who have gastric bypass to see if there are differences in binge eating, depression, and anxiety levels up to 12 months after surgery.

Participants will:

Complete questionnaires about eating habits, mood, anxiety, general health, and body image before surgery.

Undergo either a sleeve gastrectomy or a gastric bypass operation (both are standard care).

Follow a standard post-surgery diet plan.

Attend follow-up visits at 1 week, 2 weeks, 1 month, and then monthly for 12 months, where they will complete the same questionnaires again.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

This prospective cohort study compares two standard-of-care bariatric surgical procedures - laparoscopic sleeve gastrectomy (SG) and laparoscopic gastric bypass (Roux-en-Y or one-anastomosis) - with respect to postoperative changes in binge eating, depression, and anxiety. A total of 100 morbidly obese patients (50 per arm) aged 18-60 years with a body mass index ≥35 kg/m² (or ≥30 kg/m² with at least one obesity-related comorbidity) will be recruited from the General Surgery department at Kasr Alainy Teaching Hospital, Cairo University.

The choice of procedure is determined by a preoperative multidisciplinary evaluation considering baseline BMI, presence of gastroesophageal reflux disease, type 2 diabetes mellitus, and patient preference after detailed counseling. All operations are performed under general anesthesia; SG uses a 36-Fr bougie.

Validated Arabic versions of the following instruments are administered at baseline and at each postoperative visit (1 week, 2 weeks, 1 month, and monthly thereafter for 12 months):

Binge Eating Scale (BES) - primary outcome for binge eating

Beck Depression Inventory-II (BDI-II) - primary outcome for depression

Beck Anxiety Inventory (BAI) - primary outcome for anxiety

General Health Questionnaire-28 (GHQ-28)

Body Shape Questionnaire-14 (BSQ-14)

Eating Attitude Test-26 (EAT-26)

Secondary outcomes include changes in GHQ-28, BSQ-14, EAT-26 scores, and weight loss (absolute weight and BMI). Data will be analyzed using SPSS version 27, with appropriate parametric and non-parametric tests for between- and within-group comparisons. The significance level is set at p ≤ 0.05. The study is powered (80%, alpha 5%) to detect a difference in binge eating prevalence between SG (18.4%) and gastric bypass (1.3%) at one year, requiring 92 evaluable patients; 100 will be enrolled to accommodate potential loss to follow-up.

The study has been approved by the Cairo University Faculty of Medicine Research Ethics Committee (REC approval number N-64-2026, dated 7 March 2026). All participants provide written informed consent.

Studietype

Ingrijpend

Inschrijving (Geschat)

100

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

  • Egypte
    • Al-Manial Cairo
      • Cairo, Al-Manial Cairo, Egypte, 11956
        • Werving
        • Faculty of Medicine Cairo University
        • Contact:
          • Ahmed
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Age between 18 and 60 years
  • Body Mass Index (BMI) ≥ 35 kg/m² without comorbidities, OR BMI ≥ 30 kg/m² with at least one obesity-related medical comorbidity (e.g., type 2 diabetes, hypertension, obstructive sleep apnea, dyslipidemia)
  • Patient is generally fit for laparoscopic surgery and general anesthesia as determined by preoperative evaluation
  • Patient agrees to comply with postoperative lifestyle changes (dietary modifications and follow-up schedule)
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Age < 18 years or > 60 years
  • Inability or unwillingness to adhere to postoperative lifestyle changes
  • Contraindication to surgery: American Society of Anesthesiologists (ASA) class IV or higher
  • History of receiving radiotherapy or chemotherapy for cancer treatment
  • Active substance use disorder or uncontrolled severe psychiatric illness that would impair ability to comply with study procedures (e.g., active psychosis, severe suicidal ideation)
  • Pregnant or breastfeeding women (pregnancy test performed preoperatively per institutional protocol)
  • Previous bariatric surgery (revisional surgery excluded)
  • Untreated thyroid disorder (e.g., hypothyroidism or hyperthyroidism)

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Laparoscopic Sleeve Gastrectomy (SG)
Participants undergo laparoscopic sleeve gastrectomy using a 36-French bougie. Standard perioperative and postoperative care according to bariatric surgery protocol. Follow-up at 1 week, 2 weeks, 1 month, then monthly for 12 months. Outcome assessments include Binge Eating Scale (BES), Beck Depression Inventory-II (BDI-II), Beck Anxiety Inventory (BAI), GHQ-28, BSQ-14, and EAT-26.
Procedure: Laparoscopic Sleeve Gastrectomy
Laparoscopic sleeve gastrectomy performed using a 36-French bougie. The greater curvature of the stomach is resected, creating a tubular gastric sleeve. Standard perioperative care including antibiotic prophylaxis and DVT prophylaxis. Postoperative liquid diet for 15 days, then soft diet for one month, followed by gradual introduction of regular diet avoiding fatty and high-sugar foods.
Actieve vergelijker: Gastric Bypass (One Anastomosis or Roux-en-Y)
Participants undergo gastric bypass (either one anastomosis gastric bypass - OAGB, or Roux-en-Y gastric bypass - RYGB) based on preoperative multidisciplinary evaluation. Standard perioperative and postoperative care. Same follow-up schedule and outcome assessments as the SG arm.
Procedure: Gastric Bypass
Gastric bypass surgery performed either as Roux-en-Y gastric bypass (RYGB) or one anastomosis gastric bypass (OAGB) based on preoperative multidisciplinary evaluation. Includes creation of a small gastric pouch and an anastomosis to the small bowel. Standard perioperative and postoperative care same as sleeve gastrectomy.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Composite Mental Health Score (Simple Sum)
Tijdsspanne: Baseline, 6 months, 12 months
Simple sum of raw scores from three scales: Binge Eating Scale (BES, 0-46) + Beck Depression Inventory-II (BDI-II, 0-63) + Beck Anxiety Inventory (BAI, 0-63). Minimum total = 0 (best mental health). Maximum total = 172 (worst mental health). Higher score = worse mental health. Primary endpoint is change from baseline to 12 months (lower score = improvement).
Baseline, 6 months, 12 months
Binge Eating Scale (BES) Score Change
Tijdsspanne: Baseline, 6 months, 12 months
16-item self-report questionnaire. Each item scored 0-3. Total raw score range: minimum 0, maximum 46. Higher score = more severe binge eating. Clinical interpretation: 0-17 = no significant binge eating; 18-26 = moderate binge eating; 27-46 = severe binge eating.
Baseline, 6 months, 12 months
Beck Depression Inventory-II (BDI-II) Score Change
Tijdsspanne: Baseline, 6 months, 12 months
21-item self-report inventory. Each item scored 0-3. Total raw score range: minimum 0, maximum 63. Higher score = more severe depression. Clinical interpretation: 0-13 = minimal depression; 14-19 = mild depression; 20-28 = moderate depression; 29-63 = severe depression.
Baseline, 6 months, 12 months
Beck Anxiety Inventory (BAI) Score Change
Tijdsspanne: Baseline, 6 months, 12 months
21-item self-report questionnaire. Each item scored 0-3. Total raw score range: minimum 0, maximum 63. Higher score = more severe anxiety. Clinical interpretation: 0-7 = minimal anxiety; 8-15 = mild anxiety; 16-25 = moderate anxiety; 26-63 = severe anxiety.
Baseline, 6 months, 12 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Body Shape Questionnaire-14 (BSQ-14) Score Change
Tijdsspanne: Baseline, 6 months, 12 months
14-item self-report measure of body shape satisfaction. Each item scored 1 (never) to 6 (always). Total raw score range: minimum 14, maximum 84. Lower score = greater body shape satisfaction (better). Higher score = lower satisfaction (more dissatisfaction). Clinical interpretation: score ≤ 34 = good satisfaction; score 35-50 = moderate dissatisfaction; score >50 = marked to severe dissatisfaction (poor satisfaction).
Baseline, 6 months, 12 months
General Health Questionnaire-28 (GHQ-28) - Likert Score
Tijdsspanne: Baseline, 6 months, 12 months
28-item self-report screening tool for minor psychiatric disorders. Likert scoring (0-1-2-3 per item) is used. Total raw score range: minimum 0, maximum 84. Higher score = worse psychological distress. A total score greater than 23 suggests probable psychiatric caseness (anxiety or depression disorder). Four subscales (each 0-21): A = somatic symptoms (items 1-7), B = anxiety/insomnia (8-14), C = social dysfunction (15-21), D = severe depression (22-28).
Baseline, 6 months, 12 months
Eating Attitude Test-26 (EAT-26) Score Change
Tijdsspanne: Baseline, 6 months, 12 months
26-item screening tool for disordered eating attitudes. Scoring: Always=3, Usually=2, Often=1, Sometimes=0, Rarely=0, Never=0. Item 26 is reverse scored (Always=0, Never=3). Total raw score range: minimum 0, maximum 78. Higher score = more pathological eating attitudes. A score of 20 or higher suggests possible eating disorder (anorexia nervosa, bulimia nervosa, or binge eating disorder) and needs clinical interview.
Baseline, 6 months, 12 months
Percent Total Weight Loss (%TWL)
Tijdsspanne: 6 months, 12 months
Calculated as: [(Baseline weight in kg - current weight in kg) / baseline weight in kg] × 100. Higher percentage = greater weight loss. Can be negative if patient gains weight. Successful weight loss after bariatric surgery is often defined as %TWL ≥ 20% at 12 months.
6 months, 12 months
Body Mass Index (BMI) Change
Tijdsspanne: Baseline, 6 months, 12 months
Body Mass Index calculated as weight in kilograms divided by height in meters squared (kg/m²). Weight measured using a calibrated scale; height measured at baseline using a stadiometer. BMI range typically 15-60 kg/m² in this population. Lower BMI indicates healthier weight status. Clinical classification: <18.5 underweight, 18.5-24.9 normal, 25-29.9 overweight, 30-34.9 obesity class I, 35-39.9 obesity class II, ≥40 obesity class III (severe obesity).
Baseline, 6 months, 12 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Cairo University

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

11 maart 2026

Primaire voltooiing (Geschat)

1 september 2027

Studie voltooiing (Geschat)

1 september 2027

Studieregistratiedata

Eerst ingediend

15 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

15 mei 2026

Eerst geplaatst (Werkelijk)

20 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

20 mei 2026

Laatste update ingediend die voldeed aan QC-criteria

15 mei 2026

Laatst geverifieerd

1 mei 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • N-64-2026

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren